Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients

Influence du Victoza (Liraglutide,Analogue GLP-1) Sur Les Performances Gustatives, le Rassasiement Sensoriel spécifique, le Liking et le Wanting Chez Les Patients diabétiques de Type 2.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01599338

Enrollment

Registered

2012-05-16

Start date

2011-01-31

Completion date

2011-09-30

Last updated

2012-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, Type 2 Diabetes Mellitus

Keywords

Liraglutide, GLP-1 analogue, Food preference, Gustative perception, Liking, wanting, T2DM, body mass composition, leptin, ghrelin

Brief summary

Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues decrease satiety and food intake leading to a significant weight loss in patients. However, little is known about their effects on food hedonic sensations and taste perception. The aim of this study is to investigate the impact of Liraglutide on the liking and wanting components of the food reward system, taste sensitivity and sensory specific satiety in type 2 diabetes mellitus (T2DM) patients. According to the review of literature in animal models, it is expected that Liraglutide will modify food preference and gustative perception in humans. Thirty T2DM patients will be studied before and after 3 months of treatment with Liraglutide (1.2 mg/day). Same tests will be carried out on two consecutive days before and after the treatment administration. Olfactory liking, recalled liking and wanting for several food items will be assessed. Sensory specific satiety will be measured as well as detection thresholds for salty, sweet and bitter tastes. Subjects will also answer questionnaires on hunger, pleasure in eating, and food intake.

Interventions

DRUGLiraglutide

3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Type 2 diabetic patients 1. with glycemic unbalance despite anti-diabetic treatments and 2. overweight (BMI \> 25 kg/m²)

Exclusion criteria

* Impaired renal function (creatinine clearance \< 50 ml/min), * Pregnancy, * Congestive heart failure, * Acute and chronic infection, * Evolutive cancer, * Cirrhosis, * Ongoing antibiotic treatment, * Smoking (more than 5 cig/day), * Alcohol consumption (more than 20 g/day), * Aversion for the foods eaten or smelt during the study, * Impaired comprehension for cognitive tasks, * Treatments known to interfere with olfactory and gustative performances

Design outcomes

Primary

Measure	Time frame
Change in liking and wanting for protein, lipid and glucid foods	3 months
Change in sensory specific satiety for protein, lipid and glucid foods	3 months
Change in gustative detection thresholds for sweet, bitter and salty tastes	3 months
Change in appetite, desire to eat, pleasure in eating	3 months

Secondary

Measure	Time frame
Change in body mass composition (Dual Energy XRay Absorptiometry)	3 months
Change in plasma ghrelin, leptin, and HbA1c levels	3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026